A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.

The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention contain an inactive serpin gene and may be used to express any nucleic acid of interest.

Provided is an antigen fused with a porcine Fc fragment, a vaccine composition having a self-adjuvanting effect by binding an Fc fragment to various antigens, and a method of producing the antigen.

The present invention provides a combination vaccine comprising one or more antigens of Mycoplasmahyopneumoniae, one or more antigens of Porcine circovirus, and pharmaceutically acceptable excipients and/or carriers, for use in the prevention and/or treatment of porcine enzootic pneumonia and/or Porcine Circovirus-Associated Diseases (PCVAD) by administration of the vaccine into the dermis of livestock, wherein the one or more antigens of porcine circovirus comprises the PCV2 ORF2 protein in an amount from 0.1 g/dose to 10 g/dose.

This invention provides a combination vaccine which includes a porcine circovirus type 2 (PCV2) antigen and a cell free Mycoplasma hyopneumoniae (M.hyo) culture supernatant for protecting a pig against PCV2 and M.hyo infections, wherein the M.hyo culture supernatant is substantially free of PCV2 antibodies.

This invention provides a Mycoplasma hyopneumoniae (M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is a cell free M.hyo culture supernatant which is substantially free of swine IgG.

An immunogenic composition includes an immunogene and an adjuvant additive. The adjuvant additive includes a receptor associated protein (RAP) having an amino acid sequence of SEQ ID NO:1 and/or a pseudomonas exotoxin A (PE) protein. The immunogenic composition including the adjuvant additive is used in a method of enhancing immune response in hosts, whereby antibody immune response and cellular immune response for the hosts may be successfully induced and enhanced by the immunogenic composition.

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.

The present invention relates to the field of veterinary vaccines, in particular to porcine vaccines against PCV2 and associated diseases. Specifically the invention relates to the finding that a mutation is required in PCV2b ORF2 protein, to prevent its nuclear accumulation upon expression in insect cells; the mutation introduces a Proline at amino acid position 131. This allows efficient expression in insect cells, easy harvesting, and generates large amounts of virus-like particles. The VLPs are highly effective in vaccines for porcines for reduction of infection by PCV2 or of associated signs of disease.

The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.